NCT02706392: Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies

Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: ROR1+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Primary tumor or metastasis must express ROR1 (> 20%)
Exclusions: Patients with untreated unstable central nervous system (CNS) metastases and/or carcinomatous meningitis that require treatment- see trial for details

Comments are closed.

Up ↑